Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF Adjunct Therapy for Biliary Atresia
NCT03395028Phase 1Completed
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 1, open-label trial of filgrastim in biliary atresia (2 arms). Primary endpoint: Maximum Tolerated Dose at 13 months. Started Jan 2018; status: completed.
02
Drugs
filgrastim
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT03395028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395028.